NEUROG2 and central nervous system cancer: Furthermore, analysis of gene expression and survival curves was performed on the data of 676 glioma samples obtained from The Cancer Genome Atlas (TCGA) [38], showing that the patients with high expression of transcription factor ASCL1 but not NGN2 had a better survival (Figure 2B).